Prolonged anoxic exposure impacts antibiotic sensitivity profiles of Pseudomonas aeruginosa
- PMID: 40608522
- PMCID: PMC12254951
- DOI: 10.1093/femsle/fnaf066
Prolonged anoxic exposure impacts antibiotic sensitivity profiles of Pseudomonas aeruginosa
Abstract
Chronic respiratory tract infections with Pseudomonas aeruginosa frequently occur in patients with cystic fibrosis, chronic obstructive pulmonary disease, and bronchiectasis. A hallmark of these conditions is the accumulation of mucus plugs, creating oxygen-limited niches. Within these microenvironments, P. aeruginosa undergoes cellular modifications that may alter its antibiotic sensitivity. Although the acute effects of anoxia are well studied, the impact of prolonged anoxic exposure on antibiotic sensitivity remains unclear. In this study, we developed anoxic-conditioned P. aeruginosa strains by passaging a laboratory strain for 22 days in an anoxic environment. We performed time-kill assays with both parental and anoxic-conditioned strains in anoxic and aerobic environments, using ceftazidime, ciprofloxacin, colistin, and tobramycin. The anoxic-conditioned strains exhibited increased susceptibility to tobramycin and reduced sensitivity to colistin and ceftazidime. These differences were attributed to altered killing rates (as with tobramycin) or reduced regrowth under anoxic conditions (as with colistin). For ciprofloxacin, a steeper killing rate was observed against the anoxic-conditioned strains, but 24-h outcomes were similar to the parental strain. Overall, our findings demonstrate that long-term anoxia alters antibiotic sensitivity in P. aeruginosa differently than acute anoxia, with important implications for treating chronic infections in oxygen-limited environments.
Keywords: Pseudomonas aeruginosa; anoxia; antibiotic sensitivity; metabolic specialization; oxygen.
© The Author(s) 2025. Published by Oxford University Press on behalf of FEMS.
Conflict of interest statement
None declared.
Figures



Similar articles
-
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD004197. doi: 10.1002/14651858.CD004197.pub5. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Jun 2;6:CD004197. doi: 10.1002/14651858.CD004197.pub6. PMID: 28440853 Free PMC article. Updated.
-
Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.Cochrane Database Syst Rev. 2022 Nov 14;11(11):CD001021. doi: 10.1002/14651858.CD001021.pub4. Cochrane Database Syst Rev. 2022. PMID: 36373968 Free PMC article.
-
Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis: systematic review and economic model.Health Technol Assess. 2013 Dec;17(56):v-xvii, 1-181. doi: 10.3310/hta17560. Health Technol Assess. 2013. PMID: 24290164 Free PMC article.
-
Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in Pseudomonas aeruginosa clinical isolates.mBio. 2025 Jul 9;16(7):e0389624. doi: 10.1128/mbio.03896-24. Epub 2025 Jun 4. mBio. 2025. PMID: 40464559 Free PMC article.
-
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.Cochrane Database Syst Rev. 2017 Oct 5;10(10):CD009528. doi: 10.1002/14651858.CD009528.pub4. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jun 10;6:CD009528. doi: 10.1002/14651858.CD009528.pub5. PMID: 28981972 Free PMC article. Updated.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical